De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly-Reference-Cited by-同舟云学术

De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly

Published:2016-01 Issue: Volume:162 Page:27-30
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Kuhlen Michaela,Hönscheid Andrea,Loizou Loizos,Nabhani Schafiq,Fischer Ute,Stepensky Polina,Schaper Jörg,Klapper Wolfram,Siepermann Meinolf,Schuster Friedhelm,Meisel Roland,Borkhardt Arndt

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference11 articles.

1. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency;Lucas;Nat. Immunol.,2014

2. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K;Lucas;J. Exp. Med.,2014

3. A human immunodeficiency caused by mutations in the PIK3R1 gene;Deau;J. Clin. Invest.,2014

4. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling;Walsh;J. Clin. Invest.,2014

5. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation;Nagai;Ann. N. Y. Acad. Sci.,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review of mortality and survival rates for APDS;Clinical and Experimental Medicine;2024-01-27

2. PIK3R1 mutation associated with primary immunodeficiency: a case of a 14-year-old male and review of the literature: case report;Journal of Pediatrics & Neonatal Care;2023-02-20

3. Real-world evidence of mortality and survival rates in 256 individuals with APDS;2022-12-06

4. Control of CD4+ T Cell Differentiation and Function by PI3K Isoforms;Current Topics in Microbiology and Immunology;2022

5. Infections in activated PI3K delta syndrome (APDS);Current Opinion in Immunology;2021-10